Cognitive disorders

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

Retrieved on: 
Monday, July 26, 2021

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • Leveraging the experience gained from the development and marketing of a treatment for Alzheimers disease, Eisai aims to establish the Eisai Dementia Platform.
  • Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

Retrieved on: 
Monday, July 26, 2021

These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.

Key Points: 
  • These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.
  • The OVERTURE study demonstrated that gamma frequency neuro-modulation led to a significant reduction in brain atrophy in AD patients.
  • Accelerated brain atrophy is associated with cognitive decline and loss of function in AD patients and is a driver of mortality and morbidity in Alzheimers disease progression.
  • Cognito Therapeutics is a clinical-stage neuro-physiology company developing a pipeline of disease-modifying digital therapeutics that have clinically demonstrated drug-like effects using gamma frequency neuromodulation to treat neurodegenerative disorders including Alzheimers disease.

Alzheimer's Drug Discovery Foundation (ADDF) Investment Boosts Search for Digital Biomarkers for Early Alzheimer's

Retrieved on: 
Monday, July 26, 2021

The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.

Key Points: 
  • The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
  • Recent research shows that Alzheimer'salso causes subtle early changes in aspects of behaviour such as sleep, speech, interactions, and movement.
  • While undetectable to the human eye, these changes can now be picked up by commercially available digital technologies.
  • Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Improving Air Quality Reduces Dementia Risk, Multiple Studies Suggest

Retrieved on: 
Monday, July 26, 2021

While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.

Key Points: 
  • While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.
  • "But what's exciting is we're now seeing data showing that improving air quality may actually reduce the risk of dementia.
  • Air Quality Improvement May Slow Cognitive Decline and Reduce Dementia Risk in Older U.S. Women
    Although studies have found that improved air quality is associated with better respiratory health and longer life expectancy, it's unknown if improved air quality can also improve brain health.
  • Association of air quality reduction with incident dementia: effects of natural course and hypothetical air pollutant interventions using g-computation.

Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Friday, July 23, 2021

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • The companys contributions to the congress include four presentations on ADUHELM data and a total of 11 abstracts.
  • The company will also lead a late-breaking presentation on the design of the real-world observational Phase 4 study in Alzheimers disease, a prospective registry of ADUHELM, called International Collaboration for Real-World Evidence in Alzheimers Disease (ICARE AD-US).
  • Poster presentation: Reduction in Biomarkers of Alzheimers Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing Clinical Decline virtual poster #57499.

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)

Retrieved on: 
Thursday, July 22, 2021

This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimers disease and other dementias.

Key Points: 
  • This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimers disease and other dementias.
  • Cyclerion identified changes in electrophysiological measures in the recent Phase 1 Translational Pharmacology study and will be evaluating electrophysiological and cognitive endpoints in the Phase 2a study in participants with Alzheimers disease with vascular pathology.
  • Title: Clinical trial design for a Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and CNS activity of CY6463 in participants with Alzheimers disease with vascular pathology
    The poster presentation will be available beginning at 8 a.m. MT / 10 a.m.
  • The poster will also be available on the News & Events page of the Cyclerion website https://ir.cyclerion.com/news-events/event-calendar .

Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference

Retrieved on: 
Wednesday, July 21, 2021

SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimer’s Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimers Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado.
  • Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).
  • Alector plans to host a conference call to review the AL001 Phase 2 results on July 29 at 1:00 p.m.
  • Alector will also present two posters related to its AL002 Alzheimers disease (AD) program.

The Virginian Senior Living Community Launches Obie For Seniors Interactive Gaming System

Retrieved on: 
Wednesday, July 21, 2021

Obie for Seniors is an award-winning interactive gaming system that projects onto any surface - tabletops, floors, and walls - encouraging active play through touching, moving, and hand-eye coordination skills.

Key Points: 
  • Obie for Seniors is an award-winning interactive gaming system that projects onto any surface - tabletops, floors, and walls - encouraging active play through touching, moving, and hand-eye coordination skills.
  • The system is among the newest "Nana" Technology being adopted for use in the United States for individuals with Alzheimer's and related dementia.
  • Based in Israel, EyeClick is a world leader in interactive technology for 15+ years and the creator of Obie for Seniors.
  • Obie helps to enhance the conditions of senior housing facilities, hospitals, and clinics with tailored interactive games that provide residents with engagement, fun, and encourages increased mobility and cognitive skills.

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021

Retrieved on: 
Wednesday, July 21, 2021
Key Points: 
  • A poster presentation will also be given on the results of an in vivo study of E2511, Eisai's in-house discovered and developed investigational novel oral synapse regenerant.
  • Additionally, Eisai and Biogen Inc. (Nasdaq: BIIB) will hold a virtual symposium, "Defining the next-generation clinical care pathway for Alzheimer's disease: biological, technological, and healthcare perspectives," focusing on the AD treatment landscape.
  • Eisai serves as the lead in the co-development of lecanemab, an anti-Aβ protofibril antibody, which is being jointly developed by Eisai and Biogen.
  • Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia.

KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer's Disease

Retrieved on: 
Tuesday, July 20, 2021

The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.

Key Points: 
  • The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.
  • "Our Phase 3 study provides us the opportunity to gain valuable insights about the potential effectiveness of Nilotinib BE in treating early Alzheimer's.
  • KeifeRx will launch a national, multicenter, placebo-controlled, double-blind study of Nilotinib BE in early Alzheimer's disease.
  • The primary objectives of the study are to investigate the safety and efficacy of Nilotinib BE on the progression of dementia in early Alzheimer's disease.